Table 5 Univariable and multivariable... | American Society of Hematology

Table 5

Univariable and multivariable models for overall survival and progression-free survival

Variable	No.	Univariable model			Multivariable model*
Variable	No.	HR	95% CI	P	HR	95% CI	P
Overall survival
Viremia (pos vs neg)	27	3.72	0.91-15.06	.07	3.22	0.77-13.44	.11
ELISpot	25	0.41	0.18-0.94	.03	0.29	0.11-0.81	.02
PBL	27	0.14	0.02-0.96	.04	0.17	0.02-1.39	.10
CD3	27	0.20	0.06-0.71	.01	0.19	0.04-0.84	.03
CD4	27	0.21	0.06-0.76	.02	0.20	0.05-0.92	.04
CD4⁺/CD45RO⁺	27	0.17	0.04-0.65	.01	0.18	0.04-0.82	.03
CD8	27	0.32	0.12-0.87	.03	0.33	0.12-0.94	.04
CD8⁺/CD45RA⁺	27	0.30	0.10-0.88	.03	0.35	0.12-1.05	.06
CD8⁺/CD45RO⁺	27	0.36	0.13-1.01	.05	0.35	0.12-1.03	.06
TREC,† 2000 or more vs less than 2000	22	< 0.001	0.00	.005
Progression-free survival
ELISpot	25	0.54	0.33-0.90	.02	0.50	0.28-0.89	.02
CD56⁺/CD16⁺	27	0.35	0.15-0.82	.02	0.32	0.13-0.81	.02

Variable	No.	Univariable model			Multivariable model*
Variable	No.	HR	95% CI	P	HR	95% CI	P
Overall survival
Viremia (pos vs neg)	27	3.72	0.91-15.06	.07	3.22	0.77-13.44	.11
ELISpot	25	0.41	0.18-0.94	.03	0.29	0.11-0.81	.02
PBL	27	0.14	0.02-0.96	.04	0.17	0.02-1.39	.10
CD3	27	0.20	0.06-0.71	.01	0.19	0.04-0.84	.03
CD4	27	0.21	0.06-0.76	.02	0.20	0.05-0.92	.04
CD4⁺/CD45RO⁺	27	0.17	0.04-0.65	.01	0.18	0.04-0.82	.03
CD8	27	0.32	0.12-0.87	.03	0.33	0.12-0.94	.04
CD8⁺/CD45RA⁺	27	0.30	0.10-0.88	.03	0.35	0.12-1.05	.06
CD8⁺/CD45RO⁺	27	0.36	0.13-1.01	.05	0.35	0.12-1.03	.06
TREC,† 2000 or more vs less than 2000	22	< 0.001	0.00	.005
Progression-free survival
ELISpot	25	0.54	0.33-0.90	.02	0.50	0.28-0.89	.02
CD56⁺/CD16⁺	27	0.35	0.15-0.82	.02	0.32	0.13-0.81	.02

HR indicates hazard ratio for 1 unit change on log₁₀ scale (except viremia and TREC); pos, positive; and neg, negative.

Adjusted for patient's age, sex mismatch between patient and cords, and risk status at time of transplantation.

†

Because of the small sample size, the multivariable result is not shown. All patients who died had TREC level less than 2000. The upper 95% CI is not estimable.

View Large

This Feature Is Available To Subscribers Only